Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz(R)-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions. Data now being analyzed, interim results expected November 2024. BCC is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Oct. […]